Exelixis EXEL Collaboration — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's collaboration — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's collaboration — total revenues?
- Exelixis (EXEL) reported collaboration — total revenues of $55.84M in Q1 2026.
- How has Exelixis's collaboration — total revenues changed year-over-year?
- Exelixis's collaboration — total revenues increased by 32.4% year-over-year, from $42.16M to $55.84M.
- What is the long-term trend for Exelixis's collaboration — total revenues?
- Over 4 years (2021 to 2025), Exelixis's collaboration — total revenues has grown at a -13.8% compound annual growth rate (CAGR), from $357.71M to $197.32M.
- What does collaboration — total revenues mean?
- Total revenue earned from strategic partnerships and licensing agreements with other companies.
- How do you interpret collaboration — total revenues?
- An increase suggests successful achievement of development milestones or strong commercial performance of partnered assets, while a decrease may indicate fewer active collaborations or the conclusion of milestone-based payment cycles.
- How does collaboration — total revenues compare across companies?
- Comparable to 'Collaboration Revenue' or 'Licensing and Milestone Revenue' reported by other mid-to-large cap biotechnology firms that utilize a partnership-heavy commercialization model.